The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis

British Journal of Ophthalmology

Volumn 89, Issue 11, 2005, Pages 1442-1444

  Koc, Feray ^a,c   Kavuncu, S ^a   Kansu, T ^b   Acaroglu, G ^a   Firat, E ^a  

^a Ankara Ulucanlar Eye Research Hospital   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

APRACLONIDINE; COCAINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FEMALE; HORNER SYNDROME; HUMAN; MALE; MYDRIASIS; PARESIS; PRIORITY JOURNAL; UPPER EYELID;

ADRENERGIC ALPHA-AGONISTS; ADULT; ANISOCORIA; BLEPHAROPTOSIS; CLONIDINE; DIABETIC NEUROPATHIES; FEMALE; HORNER SYNDROME; HUMANS; MALE; MIDDLE AGED; MIOSIS; SENSITIVITY AND SPECIFICITY;

EID: 27344437363     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2005.074492     Document Type: Article

References (17)

1. Zeitzer JM, Ayas NT, Wu AD, et al. Bilateral oculosympathetic paresis associated with loss of nocturnal melatonin secretion in patients with spinal cord injury. J Spinal Cord Med 2005;28:55-9.
2. Pittasch D, Lobmann R, Behrens-Baumann W, et al. Pupil signs of sympathetic autonomic neuropathy in patients with type 1 diabetes. Diabetes Core 2002;25:1545-50.
3. Toth C, Fletcher WA. Autonomic disorders and the eye. J Neuroophthalmol 2005;25:1-4.
4. Morales J, Brown SM, Abdul-Rahim AS, et al. Ocular effects of apraclonidine in Horner syndrome. Arch Ophthalmol 2000;118:951-4.
5. Bacal DA, Levy SR. The use of apraclonidine in the diagnosis of Horner syndrome in pediatric patients. Arch Ophthalmol 2004;122:276-9.
6. Brown SM, Aouchiche R, Freedman KA. The utility of 0.5% apraclonidine in the diagnosis of Horner syndrome. Arch Ophthalmol 2003;121:1201-3.
7. Robin A, Pollack I, deFaller J. Effects of topical ALO2145 (p-aminoclonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy. Arch Ophthalmol 1987;105:1208-11.
8. Robin A, Pollack I, House B, et al. Effects of ALO2145 on intraocular pressure following argon laser trabeculoplasty. Arch Ophthalmol 1987;105:646-50.
9. Pollack I, Brown R, Crandall A, et al. Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical 1% apraclonidine. Arch Ophthalmol 1988;106:754-7.
10. Crosson CE, Heath AR, DeVries GW, et al. Pharmacological evidence for heterogeneity of ocular alpha 2 adrenoceptors. Curr Eye Res 1992;11:963-70.
11. Potter DE, Crosson CE, Heath AR, et al. Review: alpha 2 DA2 agonists as antiglaucoma agents: comparative pharmacology and clinical potential. J Ocul Pharmacol 1990;6:251-7.
12. Langham ME, Weinstein GW. Horner's syndrome:ocular supersensitivity to adrenergic amines. Arch Ophthalmol 1967;78:462-9.
13. Thompson HS, Mensher JH. Adrenergic mydriasis in Horner's syndrome: hydroxyamphetamine test for diagnosis of postganglionic defects. Am J Ophthalmol 1971;72:472-80.
14. Robin AL. Short-term effects of unilateral 1% apraclonidine therapy. Arch Ophthalmol 1988;106:912-15.
15. Abrarns DA, Robin AL, Pollack IP, et al. The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers. Arch Ophthalmol 1987;105:1205-7.
16. Jampel HD, Robin AL, Quiqley HA, et al. Apraclonidine a one-week dose-response study. Arch Ophthalmol 1988;106:1069-72.
17. Stewart WC, Laibovitz R, Horwitz B, et al. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Arch Ophthalmol 1996;114:938-42.